Start Date:6/28/2022
Start Time:4:00 PM CEST
Duration:120 minutes
Abstract:
Inventiva’s leadership is hosting a KOL event on the heels of the EASL-ILC conference to provide a corporate update and updates on the pivotal Phase III clinical trial, NATiV3, and the Legend Phase IIa combination study.
In addition, we will provide an update on the field of NASH and an overview of the scientific abstracts presented during the EASL–ILC conference.
If you're already registered for the Inventiva KOL event webcast, click below:
ALREADY REGISTERED?
Speakers
Frederic Cren, MA/MBA Chairman, CEO and cofounder Inventiva Frederic has served as our Chief Executive Officer since co-founding Inventiva in 2011, and as the chairman of our board of directors since May 2016. Previously, he served as the General Manager of Research of Abbott Laboratories, a pharmaceutical company, from 2010 until 2012. Prior to Abbott, Mr. Cren held a number of roles at Solvay Pharmaceuticals, a pharmaceutical company, and at Laboratoires Fournier SA, a pharmaceutical company, prior to its acquisition by Solvay in 2005. Positions at Laboratories Fournier included: Vice-President Strategic Marketing and Vice-President U.S. Operations, as well as serving as a member of the Executive Committee. Positions at Solvay included: Head of Business Strategy and Portfolio and Senior Vice-President of the Research Division, as well as serving as a member of the Executive Committee. Mr. Cren began his career with Boston Consulting Group, where he worked from 1993 to 2002. He received a master’s degree in Business Administration from INSEAD, a master’s degree in International Relations from Johns Hopkins University and a bachelor’s degree in Economics from Paris IX Dauphiné University.
Pierre Broqua, Ph.D. Chief Scientific Officer and cofounder Inventiva Pierre has served as our Chief Scientific Officer since co-founding Inventiva in 2011, and as our Deputy Chief Executive Officer as well as a member of our board of directors since May 2016. Previously, Dr. Broqua served as a Head of Research for Abbott Laboratories from 2010 until 2012 and as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010. Prior to Solvay, Dr. Broqua was the Director of Research Project for Laboratoires Fournier SA from 2002 to 2005. He is a Doctor of pharmacology from the University of Paris Descartes and also has a master’s degree in Chemistry and Biochemistry from the Université Pierre et Marie Curie, Paris.
Michael Cooreman, MD Chief Medical Officer Inventiva Prior to joining Inventiva in October 2020, Dr. Michael Cooreman has been Vice President, Science and Medicine, in charge of Global Research and Development, Gastroenterology and Hepatology, at Ferring Pharmaceuticals in the U.S. since 2017. He previously held numerous U.S.-based positions as CMO and Executive Director in global roles at leading pharmaceutical and biotechnology companies, including Takeda Pharmaceuticals, Merck, Mitsubishi Tanabe, ImmusanT and Novartis, covering the four major regulatory regions U.S., EU, Japan and China. Over the years, Dr. Cooreman has developed a strong expertise in translational medicine, clinical pharmacology and clinical product development.
Of dual US and Belgian citizenship, Dr. Cooreman is trained as an internist and gastroenterologist-hepatologist, with a special interest in metabolic and immune-mediated liver and gastrointestinal diseases, as well as viral hepatitis, cirrhosis and oncology. He holds a Doctor of Medicine degree from the University of Louvain, Belgium, and a doctorate from the Heinrich Heine University in Dusseldorf, Germany
Prof. Sven Francque Chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp Antwerp University Hospital Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France. He has a long-standing interest and expertise in non-alcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression and leading to his PhD in 2011. His research unit continues to study pathophysiological mechanisms of NASH. He is also conducting clinical research and his unit is partner in several research consortia supported by the European Commission and by the Innovative Medicines Initiative with a focus on NASH pathophysiology, biomarker research and hepatocellular carcinoma. His clinical trial unit participates from the early days of clinical trials in NASH in many clinical trials in the field. Prof. Francque is as scientific committee member involved in the design of several phase 2 and current phase 3 trials in NAFLD and is national and international lead PI of several of these trials. He is author/co-author of over 180 papers in peer-reviewed journals and authored several book chapters on NAFLD. He is editor of JHep Reports, the open-access journal of the European Association for the Study of the Liver. He is senior clinical researcher for the Research Fund of the Flemish government. He is currently chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and senior full professor of medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp. He is scientific coordinator of the Belgian Week of Gastroenterology, the Belgian national research meeting of all scientific societies in gastroenterology and hepatology in Belgium. He coordinated the Belgian guidelines on NAFLD and more recently the EASL and EASO-endorsed NAFLD patient guideline.
Dr. Stephen A. Harrison Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research Pinnacle Clinical Research He earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology.
Dr. Harrison served as a Professor of Medicine at the Uniformed Services University of the Health Sciences and is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is a past Associate Editor for Hepatology and is currently an Associate Editor for Alimentary Pharmacology and Therapeutics. He is a peer-reviewer for more than 20 medical journals andisinternationally known for studies in hepatitis C and non-alcoholic fatty liver disease with close to 200peer reviewed publications in these fields.
Dr. Harrison most recently served as a Colonel in the United States Army. Retiring in 2016, he concluded 20 years of dedicated service to his country and served as the Director of Graduate Medical Education at Brooke Army Medical Center, Associate Dean for the San Antonio Uniformed Services Health Education Consortium and Gastroenterology Consultant to the Army Surgeon General.
Dr. Onno Holleboom Internist, faculty member & Principal Investigator Amsterdam University Medical Center Dr. A.G. (Onno) Holleboom MD PhD is an internist registered in Vascular Medicine and Endocrinology, assistant professor at the Department of Vascular Medicine and Principal Investigator at Amsterdam UMC. He has a multidisciplinary clinic for patients with NAFLD together with hepatology including clinical trials. Within the NAFLD-NL consortium and supported by the MLDS foundation, he is developing care paths for NAFLD together with Leiden UMC and Radboud MC Nijmegen. Together with prof. Max Nieuwdorp, he runs a research group with 6 PhD candidates focussing on genetic and gut microbial drivers of NAFLD in three cohort studies, as well as more fundamental work on lipid droplet and inflammatory pathways. He has published 64 peer-reviewed articles, including in Circulation and Cell Metabolism and received various prestigious grants, a.o. from The Netherlands Organization for Scientific Research and the Amsterdam UMC Fellowship.
|
Inventiva KOL event
Registration Is Closed
|
|
|